Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22266
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheung, Yee-Ming Melody-
dc.contributor.authorVan, Karen-
dc.contributor.authorLan, Lan-
dc.contributor.authorBarmanray, Rahul-
dc.contributor.authorQian, Sarah Y-
dc.contributor.authorShi, William Y-
dc.contributor.authorWong, Jennifer L A-
dc.contributor.authorHamblin, Peter S-
dc.contributor.authorColman, Peter G-
dc.contributor.authorTopliss, Duncan J-
dc.contributor.authorDenholm, Justin T-
dc.contributor.authorGrossmann, Mathis-
dc.date.accessioned2019-12-12T23:08:27Z-
dc.date.available2019-12-12T23:08:27Z-
dc.date.issued2019-03-
dc.identifier.citationInternal Medicine Journal 2019; 49(3): 364-372en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22266-
dc.description.abstractReports from resource-poor countries have associated thionamide- and para-aminosalicylate sodium (PAS)-based treatment of multi-drug-resistant tuberculosis (MDR-TB) with the development of hypothyroidism. To identify predictors and assess the cumulative proportions of hypothyroidism in patients treated for MDR-TB with these agents in Australia. Retrospective multicentre study of MDR-TB patients from five academic centres covering tuberculosis (TB) services in Victoria, Australia. Patients were identified using each centre's pharmacy department and cross checked with the Victorian Tuberculosis Program. Hypothyroidism was categorised as subclinical if the thyroid-stimulating hormone was elevated and as overt if free thyroxine (fT4) was additionally reduced on two separate occasions. Our main outcome measured was the cumulative proportion of hypothyroidism (at 5 years from treatment initiation). Of the 29 cases available for analysis, the cumulative proportion of hypothyroidism at 5 years was 37% (95% confidence interval (CI): 0-57.8%). Eight of the nine affected cases developed hypothyroidism within the first 12 months of treatment. Hypothyroidism was marginally (P = 0.06) associated with higher prothionamide/PAS dosing and was reversible with cessation of the anti-tuberculosis medication. Prothionamide/PAS treatment-associated hypothyroidism is common in MDR-TB patients in Australia, emphasising the importance of regular thyroid function monitoring during this treatment. Thyroid hormone replacement, if initiated, may not need to be continued after MDR-TB treatment is completed.en_US
dc.language.isoeng-
dc.subjectdrug resistanceen_US
dc.subjectdrug-related side-effects and adverse reactionsen_US
dc.subjectthyroid diseaseen_US
dc.subjecttuberculosisen_US
dc.titleHypothyroidism associated with therapy for multi-drug-resistant tuberculosis in Australia.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternal Medicine Journalen_US
dc.identifier.affiliationDepartment of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Endocrinology and Diabetes, Western Health, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationDiabetes and Vascular Medicine Unit, Monash Health, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDiabetes and Vascular Medicine Research Program, Monash Centre for Health Research and Implementation, School of Public Health, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, Victoria, Australiaen_US
dc.identifier.affiliationVictorian Tuberculosis Program, Melbourne Health, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationDepartment of Medicine-Western Precinct, The University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationMelbourne Medical School, The University of Melbourne, Victoria, Australiaen_US
dc.identifier.doi10.1111/imj.14085en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3875-5698en_US
dc.identifier.orcid0000-0003-1224-6908en_US
dc.identifier.orcid0000-0002-1433-2239en_US
dc.identifier.orcid0000-0002-4304-8333en_US
dc.identifier.orcid0000-0002-9214-6431en_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.pubmedid30151969-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
local.name.researcherCheung, Yee-Ming Melody
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.